Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gene test pick the right blood pressure pill for black patients?

NCT ID NCT04840342

Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug eplerenone works better than amlodipine for controlling high blood pressure in Black adults who carry a specific gene variant (LSD1 risk allele). About 300 participants will follow a controlled diet and take escalating doses of one of the two drugs for four weeks. The goal is to see if a gene-guided approach can improve blood pressure control and reduce kidney damage in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Eplerenone and amlodipine
What this could lead to
If successful, this could point toward a more effective, gene-targeted treatment for high blood pressure in Black patients with a specific genetic variant.
What could go wrong
This is a phase 4 trial with a moderate sample size, but it only includes Black adults with a specific gene variant, so results may not apply to everyone. The study is also not yet recruiting, and outcomes may not lead to a new standard of care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

17 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * untreated as well as currently treated hypertensives * rs587168 allele carriers * not on more than two anti-hypertensives * normal renal, metabolic, electrolyte, and CBC laboratory tests * self-identified Black race * age \>17 yrs. Exclusion Criteria: * known cardiac disease other than HTN * renal, circulatory or neurologic diseases * diabetes * smoking * secondary HTN as indicated by history, physical examination or screening blood and urine tests * smoking * any drug therapy, except for anti-hypertensives and stable thyroid medication replacement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperaldosteronism hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension Mineralocorticoid excess

Contacts and locations

Locations

  • Brigham and Women's

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.